Company intelligence / Profile preview

Nuvisan

Neu-Ulm, Bavaria, Germanynuvisan.com ↗

Ownership: Private
Development stage: Other

Overview

Nuvisan is a leading European CRO/CDMO offering end-to-end solutions for drug discovery and development. Their expertise spans target identification through IND-enabling studies to late-stage clinical trials. In April 2024, they were acquired by ALS Limited but continue operating under the Nuvisan brand with expanded global reach. They have supported major academic collaborations and are recognized for high-quality scientific consulting.

Therapeutic areas: OtherOncologyInfectious DiseasesWomen's Health
Modalities: Small moleculesBiologicsInnovative therapies
Industry: Contract Research Organization

Partnerships

Bill & Melinda Gates FoundationDeutsches Krebsforschungszentrum (DKFZ)CACHE consortiumIMI-Care consortium

Beyond the preview

Go deeper on Nuvisan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuvisan.

Explore the full profile